source · text/csv
source_34dab4cff6e443a7
sha256 3381896358fa0ac7e289a23e8770fc91ec887f8b5fc505abe979ee75232516d6
by researka:v2 · 2026-06-24 18:37:06.122585+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b",
"researka_submission_id": "3af2fac0-d3ac-4f2e-a8dc-bb9295572ad0",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/ea8f0afd-dc89-418d-b158-6e496c6cfe3b/sidecars/evidence_table.csv"
}